Pfizer’s Sigvotatug Vedotin Misses Survival Goal in NSCLC Trial
Pfizer’s Phase 3 trial for sigvotatug vedotin in previously treated metastatic non-small cell lung cancer failed to meet its overall survival endpoint compared to docetaxel, though the drug showed favorable safety and suggested stronger benefit in second-line patients.
Pfizer announced that its investigational antibody-drug conjugate sigvotatug vedotin did not achieve a statistically significant improvement in overall survival versus docetaxel in a Phase 3 trial for previously treated metastatic non-small cell lung cancer (NSCLC).
The drug did maintain a manageable safety profile. Subgroup analysis indicated a stronger trend toward benefit among second-line patients, though the primary endpoint was missed.
The outcome may impact Pfizer’s oncology pipeline expectations, though the company will likely review further subgroup data before deciding on next steps.
Source: First Squawk